Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 120Lymphoma 90Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Burkitt Lymphoma 31Leukemia 27Multiple Myeloma 26Lymphoma, Non-Hodgkin 26Lymphoma, Follicular 26Hodgkin Disease 24Lymphoma, Mantle-Cell 18Neoplasms 16Lymphoma, T-Cell, Peripheral 16Lymphoma, B-Cell 14Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, Large-Cell, Anaplastic 11Dendritic Cell Sarcoma, Interdigitating 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Neoplasms, Plasma Cell 7Neoplasm Metastasis 7Waldenstrom Macroglobulinemia 6Primary Myelofibrosis 6Lymphoma, T-Cell 6Immunoblastic Lymphadenopathy 6HIV Infections 5Graft vs Host Disease 5Blast Crisis 5

Interventions

prednylidene 1deltacortene 1apalutamide 1Prednisone 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1BAY 86-7548 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Stage II Prostate Adenocarcinoma × Prednisone × Clear all
NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡